SCHEMBL20140324

SCHEMBL20140324

CCOC(=O)c1nc(Cc2ccccc2F)c2cccnn12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.44
GUCY1A1 Q02108 2/20 0.43
GUCY1B1 Q02153 2/20 0.43
KCNH2 Q12809 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
SLC26A6 Q9BXS9 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
POLB P06746 1/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
ADORA3 P0DMS8 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
GLA P06280 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20140303 0.83 GUCY1A1 (0.44) GUCY1A1GUCY1B1KCNH2KMT2AMEN1
SCHEMBL20140279 0.79 KMT2A (0.39) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3583623 0.75 KDM4E (0.44) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL9733754 0.71 ALDH1A1 (0.44) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL20140419 0.71 GUCY1A1 (0.37) GUCY1A1GUCY1B1KCNH2KMT2AMEN1
SCHEMBL21787186 0.70 AR (0.38) GUCY1A1GUCY1B1KCNH2KMT2AMEN1
SCHEMBL3582571 0.69 NPC1 (0.46) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3587879 0.69 GUCY1A1 (0.52) GUCY1A1GUCY1B1KCNH2KMT2AMEN1
SCHEMBL5779565 0.69 L3MBTL1 (0.48) KMT2ASMN1; SMN2KDM4EALDH1A1SLC26A6
SCHEMBL15693418 0.68 GUCY1A1 (0.67) GUCY1A1GUCY1B1KCNH2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 EP disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A PDE4A 17/4885GUCY1A1 4/4885GUCY1B1 6/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A PDE4A 17/4885GUCY1A1 4/4885GUCY1B1 6/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A PDE4A 17/4885GUCY1A1 4/4885GUCY1B1 6/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A PDE4A 17/4885GUCY1A1 4/4885GUCY1B1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.